Latest Ratios: P/E Ratio 22.5x · EV/EBITDA 14.3x · ROE 40.7%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $189.6B | $154.0B | $115.9B | $101.9B | $108.3B | $91.6B | $73.6B | $83.0B | $81.8B | $94.5B | $97.2B |
| Enterprise Value | $206.9B | $171.4B | $132.6B | $120.8B | $128.2B | $113.0B | $99.0B | $95.9B | $91.2B | $120.4B | $115.4B |
| P/E Ratio → | 22.52 | 18.10 | 243.08 | 18.00 | 23.59 | 14.73 | 598.15 | 15.40 | 15.00 | 20.41 | 7.20 |
| P/S Ratio | 6.44 | 5.23 | 4.03 | 3.76 | 3.97 | 3.36 | 2.98 | 3.70 | 3.70 | 3.62 | 3.20 |
| P/B Ratio | 8.47 | 6.81 | 6.02 | 4.48 | 5.11 | 4.35 | 4.04 | 3.66 | 3.80 | 4.61 | 5.02 |
| P/FCF | 20.05 | 16.29 | 11.25 | 13.73 | 12.98 | 8.48 | 9.79 | 9.97 | 10.94 | 8.36 | 5.97 |
| P/OCF | 18.92 | 15.37 | 10.71 | 12.73 | 11.94 | 8.05 | 9.01 | 9.07 | 9.74 | 7.94 | 5.70 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.82 | 4.61 | 4.46 | 4.70 | 4.14 | 4.01 | 4.27 | 4.12 | 4.61 | 3.80 |
| EV / EBITDA | 14.31 | 11.85 | 29.95 | 11.73 | 13.59 | 9.44 | 17.83 | 16.86 | 9.47 | 7.82 | 6.14 |
| EV / EBIT | 17.68 | 15.84 | 79.57 | 15.48 | 18.99 | 12.18 | 37.31 | 15.59 | 10.27 | 8.22 | 6.39 |
| EV / FCF | — | 18.13 | 12.87 | 16.28 | 15.36 | 10.46 | 13.17 | 11.53 | 12.20 | 10.65 | 7.08 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.8% | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% |
| Operating Margin | 39.7% | 39.7% | 5.8% | 28.0% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% |
| Net Profit Margin | 28.9% | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.7% | 17.7% | 44.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.7% | 40.7% | 2.3% | 25.8% | 21.7% | 31.7% | 0.6% | 24.4% | 26.0% | 23.2% | 70.2% |
| ROA | 14.4% | 14.4% | 0.8% | 9.0% | 7.0% | 9.1% | 0.2% | 8.6% | 8.1% | 7.3% | 24.8% |
| ROIC | 23.1% | 23.1% | 3.2% | 13.8% | 13.2% | 17.3% | 7.7% | 9.7% | 15.9% | 25.2% | 40.2% |
| ROCE | 24.8% | 24.8% | 3.4% | 14.8% | 13.5% | 17.5% | 7.5% | 8.2% | 14.7% | 26.5% | 39.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.10 | 1.10 | 1.39 | 1.10 | 1.19 | 1.27 | 1.72 | 1.09 | 1.27 | 1.64 | 1.36 |
| Debt / EBITDA | 1.72 | 1.72 | 6.03 | 2.43 | 2.67 | 2.23 | 5.66 | 4.32 | 2.84 | 2.18 | 1.40 |
| Net Debt / Equity | — | 0.77 | 0.87 | 0.83 | 0.93 | 1.01 | 1.39 | 0.57 | 0.44 | 1.27 | 0.94 |
| Net Debt / EBITDA | 1.20 | 1.20 | 3.78 | 1.84 | 2.10 | 1.78 | 4.58 | 2.28 | 0.97 | 1.68 | 0.96 |
| Debt / FCF | — | 1.84 | 1.62 | 2.55 | 2.38 | 1.98 | 3.38 | 1.56 | 1.25 | 2.30 | 1.11 |
| Interest Coverage | 10.57 | 10.57 | 1.71 | 8.27 | 7.22 | 9.27 | 2.70 | 6.19 | 8.24 | 13.10 | 18.74 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | 1.55 | 1.60 | 1.43 | 1.29 | 1.27 | 1.40 | 3.10 | 3.38 | 2.74 | 2.12 |
| Quick Ratio | 1.40 | 1.40 | 1.45 | 1.27 | 1.15 | 1.13 | 1.26 | 3.01 | 3.30 | 2.67 | 1.95 |
| Cash Ratio | 0.81 | 0.81 | 0.96 | 0.64 | 0.57 | 0.56 | 0.65 | 2.50 | 2.84 | 2.19 | 1.29 |
| Asset Turnover | — | 0.50 | 0.49 | 0.44 | 0.43 | 0.40 | 0.36 | 0.36 | 0.35 | 0.37 | 0.53 |
| Inventory Turnover | 3.51 | 3.51 | 3.66 | 3.64 | 3.75 | 4.08 | 2.72 | 5.07 | 5.96 | 5.46 | 2.68 |
| Days Sales Outstanding | — | 60.91 | 56.11 | 62.73 | 63.91 | 60.06 | 72.32 | 58.24 | 54.88 | 53.84 | 54.22 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.1% | 2.6% | 3.4% | 3.7% | 3.4% | 3.9% | 4.7% | 3.9% | 3.6% | 2.9% | 2.5% |
| Payout Ratio | 47.0% | 47.0% | 816.3% | 67.2% | 80.8% | 57.9% | 2804.1% | 59.8% | 54.5% | 59.0% | 18.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.4% | 5.5% | 0.4% | 5.6% | 4.2% | 6.8% | 0.2% | 6.5% | 6.7% | 4.9% | 13.9% |
| FCF Yield | 5.0% | 6.1% | 8.9% | 7.3% | 7.7% | 11.8% | 10.2% | 10.0% | 9.1% | 12.0% | 16.8% |
| Buyback Yield | 1.0% | 1.2% | 1.0% | 1.0% | 1.3% | 0.6% | 2.2% | 2.1% | 3.5% | 1.0% | 11.3% |
| Total Shareholder Yield | 3.1% | 3.8% | 4.4% | 4.7% | 4.7% | 4.5% | 6.8% | 6.0% | 7.2% | 3.9% | 13.8% |
| Shares Outstanding | — | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.3B | $1.4B |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GILD stock.
Gilead Sciences, Inc.'s current P/E ratio is 22.5x. The historical average is 28.4x. This places it at the 62th percentile of its historical range.
Gilead Sciences, Inc.'s current EV/EBITDA is 14.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.1x.
Gilead Sciences, Inc.'s return on equity (ROE) is 40.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 23.7%.
Based on historical data, Gilead Sciences, Inc. is trading at a P/E of 22.5x. This is at the 62th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Gilead Sciences, Inc.'s current dividend yield is 2.09% with a payout ratio of 47.0%.
Gilead Sciences, Inc. has 78.8% gross margin and 39.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Gilead Sciences, Inc.'s Debt/EBITDA ratio is 1.7x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
HIV franchise concentration and pipeline setbacks
Metrics are mathematically derived from official filings.
Impairments Mask Core Margin Strength
Despite a Q2 2026 net margin of -134.5% due to a massive IPR&D charge, underlying gross margin held at 79.8%, per recent SEC filings, indicating stable core profitability.
The reported operating margin of -133.2% in Q2 2026 is a distortion from a one-time impairment, as prior quarters consistently showed operating margins between 32% and 43%. Excluding the charge, the operating margin would approximate 40%, aligning with the company's historical performance. This suggests that the underlying business remains highly profitable, but investors should monitor the frequency of such impairments, which may indicate recurring overpayment for acquisitions.
ROIC Volatility Reflects Acquisition Risk
ROIC swung from 5.0% in Q1 2026 to -21.4% in Q2 2026, per financial statements, driven by a $10.4B impairment, obscuring the stable mid-single-digit returns seen in prior quarters.
Over the past ten quarters, ROIC has ranged from 1.8% to 6.4% when excluding the impairment quarter, indicating a modest but stable return on invested capital. The negative ROIC in Q2 2026 is a direct result of the impairment charge, which reduced equity and net income. This volatility suggests that the company's capital allocation decisions, particularly in oncology acquisitions, carry significant risk that may not be fully captured by trailing returns.
Working Capital Cycle Lengthens Slightly
Cash conversion cycle extended to 131 days in Q2 2026 from 128 days a year earlier, per reported figures, driven by higher inventory days, though asset turnover remained stable at 0.15.
The slight increase in CCC is primarily due to DIO rising to 111 days from 109 days, while DSO improved to 57 days from 59 days. This suggests that inventory management may be becoming less efficient, possibly due to the complexity of cell therapy manufacturing. However, the low asset turnover of 0.15 reflects the capital-intensive nature of the business, and the modest changes in working capital are not alarming.
Leverage Spikes on Equity Erosion
Debt-to-equity surged to 2.23 in Q2 2026 from 0.95 in Q1, per balance sheet data, as equity halved due to impairment, though interest coverage remains negative only in the impairment quarter.
The dramatic increase in D/E is a mechanical result of the equity decline, not a change in debt levels, as total debt remained around $26B. Excluding Q2 2026, interest coverage has been comfortable, ranging from 5.0 to 15.2 over the past year. This suggests that the company's debt service capacity is intact, but the equity erosion highlights the risk of further impairments that could strain leverage ratios.
Liquidity Buffer Thins but Remains Adequate
Current ratio fell to 1.27 in Q2 2026 from 1.97 in Q1, per balance sheet data, as cash dropped to $3.2B, yet quick ratio of 1.09 indicates sufficient short-term coverage.
The decline in liquidity is primarily due to the impairment charge and a reduction in cash, but the quick ratio above 1.0 suggests that the company can cover its short-term obligations without relying on inventory sales. Given the stable cash flow generation, with FCF margin of 47.3% in Q2 2026, the liquidity position appears adequate for near-term needs, though investors should monitor if cash levels continue to decline.
P/E Misleads on Impairment Distortion
The trailing P/E of 21.55 is distorted by the Q2 2026 impairment, as forward earnings are expected to recover, making EV/EBITDA of 13.75 a more reliable valuation metric, per reported figures.
The P/E ratio is commonly misapplied to Gilead because GAAP earnings are heavily impacted by non-cash IPR&D charges, which do not reflect operational performance. In contrast, EV/EBITDA of 13.75 is less affected by these charges and provides a clearer picture of valuation relative to cash-generating ability. Investors should focus on adjusted earnings or EV/EBITDA when assessing Gilead's value, as the P/E may understate the company's true earning power.